Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS

Key Points

• Dogwood Therapeutics reported a quarterly loss of $0.34 per share, falling short of the consensus estimate of a $0.13 loss by $0.21.
• The stock rose $0.05 to $1.97, but remains well below its 12-month high of $9.50; institutional ownership stands at 9.05%.
• Analyst sentiment is mixed, with one Buy and one Sell rating, resulting in a consensus “Hold” rating and a $12.00 target price.

Dogwood Therapeutics (NASDAQ:DWTX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.21), FiscalAI reports.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ:DWTX traded up $0.05 on Thursday, hitting $1.97. The stock had a trading volume of 17,962 shares, compared to its average volume of 76,775. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50. The firm's 50 day moving average price is $1.55 and its 200-day moving average price is $2.05. The company has a market capitalization of $66.28 million, a price-to-earnings ratio of -0.19 and a beta of 1.71.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,655 shares of the company's stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities & Exchange Commission. 9.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on DWTX shares. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a report on Tuesday, May 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood's lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source